IL-17A 抑制剂治疗银屑病的研究进展

常 伟, 张 昕, 谭 献, 郭 佳敏, 陈昭 通讯
华北理工大学附属唐山市工人医院 唐山 063000

摘要

目的：银屑病是一种遗传、免疫等多种因素介导的慢性炎症性全身性疾病，其特征是红色斑块和银白色鳞屑。近年来随着靶向药物的研发不断发展，已有多种生物制剂投入市场,旨在对银屑病的治疗提供一种全新的选择。目前认为 IL23-IL17 细胞因子轴在银屑病的发病机制中起到重要作用，本文将从两种药物的临床试验以及安全性等方面系统阐述 IL-17A 抑制剂治疗中重度斑块性银屑病的疗效。为中重度银屑病提供靶向治疗策略。

关键词

关键词：银屑病；IL-17A;生物制剂;依奇珠单抗;司库奇尤单抗

参考

[1]Alwan W, Nestle F O. Pathogenesis and treatment of psoriasis: exploiting pathophysiological pathways for precision medicine[J]. Clin Exp Rheumatol, 2015, 33(5 Suppl 93): S2-6. [2]Ghoreschi K, Balato A, Enerbäck C, et al. Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis[J]. The Lancet, 2021, 397(10275): 754-766. [3]Kubo R, Muramatsu S, Sagawa Y, et al. Bath-PUVA therapy improves impaired resting regulatory T cells and increases activated regulatory T cells in psoriasis[J]. Journal of Dermatological Science, 2017, 86(1): 46-53. [4]Guan J, Yuan S, Wu H, et al. Effectiveness and safety of traditional Chinese medical bath therapy combined with ultraviolet irradiation in the treatment of psoriasis: A systematic review and meta-analysis of randomized controlled trials[J]. PloS one, 2017, 12(3): e0173276. [5]Menter A, Strober B E, Kaplan D H, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics[J]. Journal of the American Academy of Dermatology, 2019, 80(4): 1029-1072. [6]Kaushik S B, Lebwohl M G. Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents[J]. Journal of the American Academy of Dermatology, 2019, 80(1): 27-40. [7]Kragballe K, van de Kerkhof P, Gordon K B. Unmet needs in the treatment of psoriasis[J]. European Journal of Dermatology, 2014, 24(5): 523-532. [8]Furue K, Ito T, Furue M. Differential efficacy of biologic treatments targeting the TNF-α/IL-23/IL-17 axis in psoriasis and psoriatic arthritis[J]. Cytokine, 2018, 111: 182-188. [9]Ghoreschi K, Balato A, Enerbäck C, et al. Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis[J]. The Lancet, 2021, 397(10275): 754-766. [10]Chiricozzi A, Romanelli P, Volpe E, et al. Scanning the immunopathogenesis of psoriasis[J]. International journal of molecular sciences, 2018, 19(1): 179. [11]Iwakura Y, Ishigame H, Saijo S, et al. Functional specialization of interleukin-17 family members[J]. Immunity, 2011, 34(2): 149-162. [12]Hawkes J E, Yan B Y, Chan T C, et al. Discovery of the IL-23/IL-17 signaling pathway and the treatment of psoriasis[J]. The Journal of Immunology, 2018, 201(6): 1605-1613. [13]Yilmaz S B, Cicek N, Coskun M, et al. Serum and tissue levels of IL-17 in different clinical subtypes of psoriasis[J]. Archives of Dermatological Research, 2012, 304(6): 465-469. [14]Thaçi D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial[J]. Journal of the American Academy of Dermatology, 2015, 73(3): 400-409. [15]Thaçi D, Puig L, Reich K, et al. Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment: Results from the CLEAR study[J]. Journal of the American Academy of Dermatology, 2019, 81(6): 1405-1409. [16]Langley R G, Elewski B E, Lebwohl M, et al. Secukinumab in plaque psoriasis—results of two phase 3 trials[J]. New England Journal of Medicine, 2014, 371(4): 326-338. [17]Strober B, Gottlieb A B, Sherif B, et al. Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept[J]. Journal of the American Academy of Dermatology, 2017, 76(4): 655-661. [18]van de Kerkhof P C M, Griffiths C E M, Reich K, et al. Secukinumab long-term safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis[J]. Journal of the American Academy of Dermatology, 2016, 75(1): 83-98. e4. [19]Blauvelt A, Shi N, Somani N, et al. Comparison of two-year treatment adherence, persistence, discontinuation, reinitiation, and switching between psoriasis patients treated with ixekizumab or secukinumab in real-world settings[J]. Journal of the American Academy of Dermatology, 2022, 86(3): 581-589. [20]Gordon K, Blauvelt A, Langley R. Ixekizumab for treatment of moderate-to-severe plaque psoriasis: 60-week results from a double-blind phase 3 induction and randomized withdrawal study (UNCOVER-1)[C]//73rd Annual Meeting of the American Academy of Dermatology. 2015: 20-24. [21]Griffiths C E M, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials[J]. The Lancet, 2015, 386(9993): 541-551. 作者简介第一作者：常伟（1996-）男，陕西榆林人，在读硕士，研究方向：皮肤病与性病学 通讯作者：陈昭（1977-）女，河北唐山人，主任医师，研究方向：银屑病及过敏性疾病